Medulloblastoma and glioblastoma are both malignant brain tumors, but they differ in nearly every clinically meaningful way: where they grow, who they tend to strike, how they are classified at the molecular level, how they respond to treatment, and how likely a patient is to survive. Confusing the two is understandable since both names end in “-blastoma” and both are aggressive cancers of the central nervous system. Yet their biology, behavior, and outlook could hardly be more different, and understanding those differences matters for patients and families trying to make sense of a diagnosis.
Where Each Tumor Grows
Medulloblastoma arises in the posterior fossa, the lower back compartment of the skull that houses the cerebellum and brainstem. In adults it typically appears within the cerebellar hemisphere, while in children it more often sits along the midline of the cerebellum.1Ochsner Journal. Dural-Based Posterior Fossa Medulloblastoma Mimicking a Petrous Meningioma in Late Adulthood Because the cerebellum coordinates balance and fine motor control, symptoms at diagnosis often include unsteadiness, headaches, and vomiting caused by rising pressure inside the skull when the tumor blocks the normal flow of cerebrospinal fluid.
Glioblastoma, by contrast, is a tumor of the cerebral hemispheres, the large upper portions of the brain responsible for thinking, language, movement, and sensation. It can appear in almost any lobe, though the frontal and temporal lobes are common sites. Symptoms depend on location and may include seizures, personality changes, speech problems, or weakness on one side of the body. Because glioblastoma infiltrates surrounding brain tissue with finger-like projections rather than forming a clean border, surgeons face a fundamentally different challenge than they do with medulloblastoma, which tends to be more circumscribed.
Who Gets Each Tumor
Medulloblastoma is primarily a childhood cancer. It is one of the most common malignant brain tumors in children, with a peak incidence between roughly ages three and eight. Adults can develop it too, but it is uncommon after age 40. In adults, the molecular profile shifts heavily toward one particular subgroup (discussed below), which changes both prognosis and treatment planning.2MDPI Cancers. Pediatric versus Adult Medulloblastoma: Towards a Definition That Goes beyond Age
Glioblastoma runs in the opposite direction. It is overwhelmingly a disease of older adults, with a median age at diagnosis in the mid-60s. It is the most common primary malignant brain tumor in adults and is relatively rare in children. When glioblastoma does occur in younger patients, its molecular biology is often distinct enough that the 2021 WHO classification now separates pediatric-type diffuse high-grade gliomas from their adult counterparts.3PubMed Central. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
Different Cells of Origin
These two tumors spring from entirely different cell populations. Medulloblastoma originates from precursor cells in the developing cerebellum. Research has confirmed that the SHH subgroup of medulloblastoma arises from the granule cell lineage, while Group 3 and Group 4 tumors are linked to the unipolar brush cell lineage.4Neuro-Oncology. Mapping pediatric brain tumors to their origins in the developing cerebellum Experimental work has shown that the oncogenic signaling driving medulloblastoma is restricted to the hindbrain; even when the same genetic switch is forced on in forebrain progenitor cells, medulloblastoma does not form, and neither do gliomas.5Cancer Cell. Acquisition of Granule Neuron Precursor Identity Is a Critical Determinant of Progenitor Cell Competence to Form Shh-Induced Medulloblastoma
Glioblastoma, on the other hand, derives from glial cells or their precursors in the cerebral hemispheres. Glial cells are the support cells of the brain, and the transformation of these cells into a tumor involves a different set of genetic alterations altogether. This fundamental difference in the cell of origin explains why the two cancers look different under a microscope, behave differently in the body, and respond to different treatments.
Molecular Landscapes That Barely Overlap
One of the starkest contrasts between these tumors lies in their molecular profiles. Medulloblastoma is now subdivided into four consensus molecular subgroups: WNT, SHH, Group 3, and Group 4. Each has its own genetic fingerprint, demographics, and clinical behavior.6PubMed Central. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas A meta-analysis of 550 medulloblastomas found that the four subgroups are strikingly distinct in their gene expression, DNA copy-number changes, patient demographics, and survival outcomes.7PubMed Central. Molecular subgroups of medulloblastoma The WNT subgroup carries the best prognosis, with survival rates above 90 percent, while Group 3 tumors with MYC amplification fare the worst.
The distribution of these subgroups changes with age. Across all ages, Group 4 tumors are the most common at roughly 35 to 40 percent, followed by SHH at about 30 percent, Group 3 at 20 to 25 percent, and WNT at around 10 percent. In adults, however, SHH dominates, making up about 60 percent of cases, with Group 4 at 25 percent and WNT at 15 percent, while Group 3 is essentially absent.2MDPI Cancers. Pediatric versus Adult Medulloblastoma: Towards a Definition That Goes beyond Age
Glioblastoma’s molecular profile is defined by an entirely different set of markers. The key ones include IDH mutation status, TERT promoter mutations, EGFR amplification, and MGMT promoter methylation. TERT promoter mutations tend to cluster with IDH wild-type status, EGFR amplification, and chromosome 10q loss.8PubMed. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes EGFR amplification itself has been found exclusively in IDH wild-type and TERT-mutated high-grade gliomas and is mutually exclusive with a specific chromosomal change called 1p/19q codeletion.9PubMed Central. EGFR Amplification Is a Phenomenon of IDH Wildtype and TERT Mutated High-Grade Glioma MGMT promoter methylation matters because it predicts how well the tumor responds to the standard chemotherapy drug temozolomide: patients whose tumors carry this methylation tend to do better.
None of these glioblastoma markers play a meaningful role in medulloblastoma biology, and none of the medulloblastoma subgroup-defining pathways (WNT signaling, Sonic Hedgehog, MYC amplification) are relevant in glioblastoma classification. The two tumors essentially speak different molecular languages.
How Treatment Differs
Both tumors require surgery as a first step, but the goals and follow-up protocols diverge sharply. In medulloblastoma, surgeons aim for the most complete resection they can safely achieve. A large multi-cohort analysis of over 1,100 molecularly characterized medulloblastoma patients found that while subtotal resection was associated with lower overall survival in simple analysis, it was not an independent risk factor once molecular subgroup was accounted for. The study concluded that subtotal resection alone should not drive decisions about further treatment escalation.10PubMed Central. The clinical significance of sub-total surgical resection in childhood medulloblastoma: a multi-cohort analysis of 1100 patients A separate retrospective analysis showed that the survival benefit of gross total resection was strongest in Group 4 medulloblastoma with metastatic disease, while for WNT, SHH, and Group 3 tumors there was no significant difference between subtotal and gross total resection.11PubMed Central. Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup The practical takeaway is that surgeons should remove as much tumor as safely possible but should not chase every last fragment if doing so risks serious neurological harm.
After surgery, medulloblastoma treatment typically includes craniospinal irradiation, meaning radiation to the entire brain and spinal cord, because the tumor has a tendency to seed through the cerebrospinal fluid. Chemotherapy is added as well, and the specific regimen depends on risk stratification and molecular subgroup. This multimodal approach cures a substantial proportion of patients, especially children with WNT or standard-risk SHH tumors.
Glioblastoma treatment follows the Stupp protocol established in the mid-2000s: maximum safe surgical resection followed by concurrent radiation and temozolomide chemotherapy, then additional cycles of temozolomide alone. Unlike medulloblastoma, radiation is directed only at the tumor bed and a surrounding margin, not the entire brain and spine, because glioblastoma rarely spreads through the cerebrospinal fluid. Instead, it recurs locally, usually within centimeters of the original site. Despite aggressive treatment, the tumor almost invariably returns.
Spread Patterns
Medulloblastoma has a well-known propensity to spread along the cerebrospinal fluid pathways, dropping tumor cells (called “drop metastases”) down the spine. This is why staging includes an MRI of the entire spine before surgery and examination of the spinal fluid afterward. One pediatric study found drop metastases present at diagnosis in a subset of patients, and these patients were less likely to achieve complete surgical resection of the primary tumor.12Oxford University Press. Comparing pediatric medulloblastoma with and without spinal metastasis Group 3 tumors, particularly those with MYC amplification, carry the highest risk of leptomeningeal dissemination.
Glioblastoma behaves very differently. It is locally invasive, sending microscopic tendrils into surrounding brain tissue that make complete surgical removal essentially impossible. However, it very rarely metastasizes to the spine or outside the brain. The clinical problem with glioblastoma is not distant spread but local recurrence: the tumor grows back where it started, having been seeded by cancer cells that infiltrated beyond the visible tumor margin.
Why Glioblastoma Recurs So Reliably
A key reason glioblastoma is so difficult to cure lies in its stem cell population. Glioma stem cells make up a small, slow-dividing fraction of the tumor, but they can self-renew and regenerate the entire tumor. Because standard therapies preferentially kill rapidly dividing cells, these stem cells often survive radiation and chemotherapy, driving inevitable recurrence.13PubMed Central. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence This is a central reason why glioblastoma carries a median survival of only about 15 months even with full treatment.
Medulloblastoma can also recur, and when it does the outlook is poor. But its recurrence biology is different. Some medulloblastoma subgroups, particularly those with MYC amplification, show resistance to radiation. Recent research has identified a mechanism involving a protein called CDK8 that helps these tumors repair DNA damage caused by radiation, specifically by maintaining a DNA repair program in actively working genes. Blocking CDK8 disrupts this repair process and could potentially make radiation-resistant medulloblastomas more treatable.14Neuro-Oncology Pediatrics. Targeting the CDK8:Transcription-coupled DNA repair axis to overcome radioresistance in MYC-driven medulloblastoma
Prognosis and Survival
This is where the gap between the two tumors is widest. Medulloblastoma, while aggressive, is often curable. Overall five-year survival for medulloblastoma across all subgroups and age groups is roughly 70 to 80 percent, with the WNT subgroup exceeding 90 percent and Group 3 MYC-amplified tumors falling well below 50 percent. A study using the SEER database analyzed over 2,300 medulloblastoma patients and developed predictive models for one-, three-, and five-year survival, reflecting the fact that long-term survival is a realistic goal for many patients.15Nature / Scientific Reports. Deep learning models for predicting the survival of patients with medulloblastoma based on a surveillance, epidemiology, and end results analysis
Glioblastoma’s prognosis is among the worst of any cancer. Median overall survival hovers around 14 to 16 months with standard treatment, and five-year survival is in the single digits. Even patients whose tumors carry the favorable MGMT methylation marker, giving them better responses to temozolomide, typically see median survival extended to about 21 months. The disease is considered essentially incurable with current therapies.
Long-Term Effects of Surviving Medulloblastoma
Because many medulloblastoma patients are children who go on to live for decades, the long-term consequences of treatment are a major concern. Survivors frequently deal with neurological and sensory problems including hearing loss, hormonal deficiencies that affect growth and development, and an increased risk of secondary tumors later in life. Neurocognitive impairment is particularly common, with declining processing speed, attention, and working memory reported as core deficits, driven by both cerebellar damage and the effect of radiation on developing white matter.16Oxford University Press. Core deficits and quality of survival after childhood medulloblastoma: a review These cognitive changes translate into real-world difficulties including lower academic achievement, higher unemployment, and social isolation.
One particularly sobering late complication is the development of radiation-induced malignant glioma, essentially a secondary brain tumor caused by the very radiation that cured the original cancer. A case report describes a patient who developed multicentric malignant glioma years after receiving craniospinal irradiation for medulloblastoma, illustrating the difficult trade-off between curing the initial tumor and the long-term risks of the treatment.17Journal of Radiotherapy in Practice. A stereotactic solution for glioblastoma in the setting of prior craniospinal irradiation for adult medulloblastoma This is one reason researchers are actively working to reduce radiation doses in favorable-risk medulloblastoma subgroups without sacrificing cure rates.
Glioblastoma patients face a different burden. Because survival is short, the focus is more on maintaining function and quality of life during treatment rather than managing decades of late effects. Fatigue, cognitive decline from the tumor itself and from treatment, steroid side effects, and progressive neurological deterioration are the primary quality-of-life concerns. The conversation around glioblastoma tends to center on maximizing functional time rather than planning for long-term survivorship.
Emerging Therapies
The two tumors are attracting different experimental approaches, though immunotherapy is being explored for both. For glioblastoma, CAR T cell therapy has been the subject of intense investigation. Between 2015 and 2024, results from eight completed and two ongoing phase I clinical trials were published, targeting molecules including EGFR, HER2, and IL13Rα2. These cells have been safely given through both intravenous and direct-to-brain routes, but clinical results have been mixed so far.18Elsevier / Molecular Therapy. CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials The field is still working on overcoming glioblastoma’s ability to suppress the immune response and hide from engineered T cells.
For medulloblastoma, much of the research momentum is focused on molecular subgroup-specific therapy. The goal is to intensify treatment for high-risk patients (Group 3 MYC-amplified, for example) while safely reducing it for patients with excellent-prognosis subgroups like WNT, thereby sparing them unnecessary toxicity. Targeted agents aimed at the SHH pathway have shown some promise in SHH-driven tumors, and work on CDK8 inhibitors for radiation-resistant disease is in early stages. The overarching aim is to maintain high cure rates while reducing the severe late effects that currently shadow survival.
Access to Specialized Care
Both tumors benefit from treatment at specialized centers with multidisciplinary neuro-oncology teams, but access is uneven. A study at a rural tertiary care center found that only 3 of 18 pediatric medulloblastoma patients received proton-based craniospinal irradiation, a technique that reduces radiation exposure to healthy tissues compared with conventional photon radiation. All three patients who received proton therapy were Caucasian, and while the study was too small to draw firm statistical conclusions, non-Caucasian patients tended to have shorter travel times to the center, suggesting that distance and demographic factors both influence who receives advanced treatment options.19Cureus. Barriers to Receiving Proton-Craniospinal Irradiation for Pediatric Medulloblastoma Patients at a Rural Tertiary Care Center Nearly 40 percent of patients had no documented discussion of proton therapy in their medical records at all.
Glioblastoma patients face similar access issues, compounded by the fact that many are older and may have comorbidities that limit their ability to travel for specialized care. Clinical trial enrollment, which represents the best chance at accessing novel therapies like CAR T cells, is concentrated at academic medical centers in urban areas. For both tumors, geography and socioeconomic status remain significant barriers to receiving the most advanced available treatment, a problem that molecular advances alone cannot solve.
How Classification Has Changed the Picture
The 2021 WHO classification of central nervous system tumors represented a turning point for both diseases. It formally integrated molecular markers into the diagnostic criteria, meaning that a brain tumor’s classification now depends not just on how it looks under a microscope but on its genetic and epigenetic profile.3PubMed Central. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary For medulloblastoma, this codified the four-subgroup system that had been validated through years of research. For glioblastoma, it sharpened the definition by requiring IDH wild-type status, separating it from what were previously called “secondary glioblastomas” (which are now classified as IDH-mutant astrocytomas, grade 4, a biologically different disease with a somewhat better prognosis).
This reclassification has practical consequences. A patient diagnosed with a grade 4 glioma that carries an IDH mutation is no longer told they have glioblastoma, even though the tumor looks identical under a microscope. Their treatment and expected outcome differ from true IDH wild-type glioblastoma. Similarly, a medulloblastoma patient’s subgroup assignment now directly influences risk stratification and treatment intensity. The era of treating all medulloblastomas or all high-grade gliomas as a single disease is over, replaced by an approach that recognizes these are families of related but distinct entities, each demanding its own strategy.